177 Persistent MRSA bacteremia 8 References 1. Kourtis, A.P.; Hatfield, K.; Baggs, J.; Mu, Y.; See, I.; Epson, E.; Nadle, J.; Kainer, M.A.; Dumyati, G.; Petit, S.; et al. Vital Signs: Epidemiology and Recent Trends in MethicillinResistant and in Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections— United States. MMWR Morb. Mortal. Wkly. Rep. 2019, 68, 214–219. 2. Jernigan, J.A.; Hatfield, K.M.; Wolford, H.; Nelson, R.E.; Olubajo, B.; Reddy, S.C.; McCarthy, N.; Paul, P.; McDonald, L.C.; Kallen, A.; et al. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients 2012–2017. N. Engl. J. Med. 2020, 382, 1309–1319. 3. van Hal, S.J.; Jensen, S.O.; Vaska, V.L.; Espedido, B.A.; Paterson, D.L.; Gosbell, I.B. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin. Microbiol. Rev. 2012, 25, 362–386. 4. Bai, A.D.; Lo, C.K.; Komorowski, A.S.; Suresh, M.; Guo, K.; Garg, A.; Tandon, P.; Senecal, J.; Del Corpo, O.; Stefanova, I.; et al. Staphylococcus aureus bacteraemia mortality: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2022, 28, 1076–1084. 5. Yousaf, A.; Baird, G.L.; Mermel, L. Association of Infectious Disease Consultation with Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia at Low Risk for Endocarditis. Open Forum Infect. Dis. 2018, 5. 6. Goto, M.; Jones, M.P.; Schweizer, M.L.; Livorsi, D.J.; Perencevich, E.N.; Richardson, K.; Beck, B.F.; Alexander, B.; Ohl, M.E. Association of Infectious Diseases Consultation with Longterm Postdischarge Outcomes among Patients with Staphylococcus aureus Bacteremia. JAMA Netw. Open 2020, 3, e1921048. 7. Bai, A.D.; Showler, A.; Burry, L.; Steinberg, M.; Ricciuto, D.R.; Fernandes, T.; Chiu, A.; Raybardhan, S.; Science, M.; Fernando, E.; et al. Impact of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay in Staphylococcus aureus Bacteremia: Results from a Large Multicenter Cohort Study. Clin. Infect. Dis. 2015, 60, 1451–1461. 8. Pragman, A.A.; Kuskowski, M.A.; Abraham, J.; Filice, G.A. Infectious Disease Consultation for Staphylococcus aureus Bacteremia Improves Patient Management and Outcomes. Infect. Dis. Clin. Pract. 2012, 20, 261–267. 9. Holland, T.L.; Arnold, C.J.; Fowler, V.G. Clinical Management of Staphylococcus aureus Bacteremia: A review. JAMA 2014, 312, 1330–1341. 10. Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary. Clin. Infect. Dis. 2011, 52, 285–292. 11. Fowler, V.G.; Olsen, M.K.; Corey, G.R.; Woods, C.W.; Cabell, C.H.; Reller, L.B.; Cheng, A.C.; Dudley, T.; Oddone, E.Z. Clinical Identifiers of Complicated Staphylococcus aureus Bacteremia. Arch. Intern. Med. 2003, 163, 2066–2072. 12. Minejima, E.; Mai, N.; Bui, N.; Mert, M.; Mack, W.J.; She, R.C.; Nieberg, P.; Spellberg, B.; Wong-Beringer, A. Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin. Infect. Dis. 2019, 70, 566–573. 13. Minejima, E.; Bensman, J.; She, R.C.; Mack, W.J.; Tran, M.T.; Ny, P.; Lou, M.; Yamaki, J.; Nieberg, P.; Ho, J.; et al. A Dysregulated Balance of Proinflammatory and AntiInflammatory Host Cytokine Response Early during Therapy Predicts Persistence and Mortality in Staphylococcus aureus Bacteremia. Crit. Care Med. 2016, 44, 671–679.
RkJQdWJsaXNoZXIy MTk4NDMw